BDX - Becton Dickinson and Co Stock Price, Fair Value and News

233.38USD-3.77 (-1.59%)Market Closed

Market Summary

USD233.38-3.77

Market Closed

-1.59%

BDX Alerts

1 major insider sales recently.

BDX Stock Price

View Fullscreen

BDX RSI Chart

BDX Valuation

Market Cap

68.5B

Price/Earnings (Trailing)

51.42

Price/Sales (Trailing)

3.48

EV/EBITDA

18.66

Price/Free Cashflow

22.55

BDX Price/Sales (Trailing)

BDX Profitability

EBT Margin

8.34%

Return on Equity

5.2%

Return on Assets

2.46%

Free Cashflow Yield

4.43%

BDX Fundamentals

BDX Revenue

Revenue (TTM)

19.7B

Rev. Growth (Yr)

4.65%

Rev. Growth (Qtr)

7.2%

BDX Earnings

Earnings (TTM)

1.3B

Earnings Growth (Yr)

16.74%

Earnings Growth (Qtr)

91.1%

Breaking Down BDX Revenue

52 Week Range

233.38287.32

(Low)(High)

Last 7 days

1.1%

Last 30 days

-3.6%

Last 90 days

-1.0%

Trailing 12 Months

-5.7%

How does BDX drawdown profile look like?

BDX Financial Health

Current Ratio

1.41

Debt/Equity

0.62

Debt/Cashflow

0.24

BDX Investor Care

Dividend Yield

1.57%

Dividend/Share (TTM)

3.72

Shares Dilution (1Y)

1.76%

Diluted EPS (TTM)

4.51

Historical Charts for Stock Metrics

Get all data in R, Python etc through our Historical Stock Data APIs

Net sales

Year	Q1	Q2	Q3	Q4
2024	19.7B	0	0	0
2023	18.8B	19.0B	19.4B	19.5B
2022	18.7B	18.7B	18.9B	18.7B
2021	18.9B	19.6B	19.4B	18.8B
2020	17.4B	16.9B	17.1B	18.2B
2019	17.0B	17.1B	17.3B	17.4B
2018	13.5B	14.7B	16.0B	17.1B
2017	12.3B	12.2B	12.1B	12.3B
2016	12.2B	12.3B	12.5B	12.4B
2015	8.5B	9.4B	10.3B	11.2B
2014	8.2B	8.3B	8.4B	8.5B
2013	7.8B	7.9B	8.1B	8.2B
2012	7.6B	7.7B	7.7B	7.8B
2011	7.2B	7.3B	7.6B	7.6B
2010	7.2B	7.2B	7.1B	7.1B
2009	6.9B	7.0B	7.0B	7.1B
2008	0	6.6B	6.9B	6.9B
2007	0	0	6.3B	0

Get all data in R, Python etc through our Historical Stock Data APIs

GRUFITY'S FAIR VALUE MODEL

Stocks Marked 'Very Cheap' by Grufity's Fair Value Model Have Outperformed S&P 500 Index

Grufity's Fair Value model takes all the S&P 500 stocks and divides them into separate buckets based on their attractiveness. The 'Very Cheap' bucket of S&P 500 has greatly outperformed S&P 500 Index. Conversely, S&P500 stocks considered 'Very Expensive' by the model underperformed the S&P500 index in the past three years. Grufity Fair Value is available for 2300+ stocks, including 90% of S&P 500 stocks. Grufity's Fair Value Model separates high-return stocks from low-return stocks.

Returns of $10,000 invested in:

Very Cheap Stocks: $17,289
S&P 500 Index: $12,922
Very Expensive Stocks: $11,022

Grufity's Fair Value model does a great job in separating High Performing Stocks from Low Performing ones in the S&P 500 list.

S&P 500 Index

Very Expensive Stocks

Very Cheap Stocks

Try For Just $1.99

Tracking the Latest Insider Buys and Sells of Becton Dickinson and Co

Filter Transactions

Datesorted ascending	Name	Buy/Sell	$ Value	Avg. Price	# Shares	Title
Apr 30, 2024	garrison michael david	sold	-399,269	232	-1,715	evp & president medical
Apr 04, 2024	neal shana carol	sold (taxes)	-	-	-1,921	evp and chief people officer
Mar 14, 2024	spoerel thomas j	sold	-67,197	238	-282	svp,controller&chief acct off
Mar 01, 2024	garrison michael david	sold (taxes)	-	-	-178	evp & president medical
Mar 01, 2024	spoerel thomas j	sold (taxes)	-	-	-36.00	svp,controller&chief acct off
Mar 01, 2024	ezell antoine c	sold (taxes)	-	-	-282	evp, president na & cmo
Jan 23, 2024	waldstreicher joanne	acquired	-	-	900	-
Jan 23, 2024	jones christopher ian montague	acquired	-	-	900	-
Jan 23, 2024	eckert r andrew	acquired	-	-	900	-
Jan 23, 2024	scott bertram l	acquired	-	-	900	-

Which funds bought or sold BDX recently?

View All Details

Datesorted ascending	Fund Name	Type	% Chg	$ Change	$ Held	% Portfolio
May 06, 2024	Broderick Brian C	added	22.06	265,176	1,375,820	0.29%
May 06, 2024	Integrated Advisors Network LLC	reduced	-0.91	2,186	406,085	0.02%
May 06, 2024	Empirical Finance, LLC	added	3.52	123,626	2,567,050	0.16%
May 06, 2024	Parallel Advisors, LLC	reduced	-5.59	-47,637	1,091,570	0.03%
May 06, 2024	Metis Global Partners, LLC	reduced	-10.13	-250,265	2,593,520	0.09%
May 06, 2024	Hartford Funds Management Co LLC	added	20.42	92,571	509,247	0.05%
May 06, 2024	Advisory Services Network, LLC	added	5.12	196,706	3,143,770	0.07%
May 06, 2024	SFE Investment Counsel	reduced	-18.42	-1,106,850	5,326,610	1.21%
May 06, 2024	Manchester Capital Management LLC	added	2.55	185,854	4,754,010	0.58%
May 06, 2024	Candriam S.C.A.	added	157	36,317,200	58,854,700	0.38%

Are Funds Buying or Selling BDX?

Are funds buying BDX calls or puts?

Calls

Puts

No. of funds holding Calls - Puts

Net Call Options

No. of funds that own BDX

No. of Funds

BDX Alerts

1 major insider sales recently.

Unveiling Becton Dickinson and Co's Major ShareHolders

Date Filed	Name of Filer	Percent of Class	No. of Shares	Form Type
Feb 16, 2024	price t rowe associates inc /md/	3.6%	10,391,519	SC 13G/A
Feb 14, 2024	price t rowe associates inc /md/	3.6%	10,391,519	SC 13G/A
Feb 13, 2024	vanguard group inc	9.02%	26,123,070	SC 13G/A
Jan 26, 2024	blackrock inc.	7.9%	22,774,866	SC 13G/A
Feb 14, 2023	price t rowe associates inc /md/	6.7%	18,962,386	SC 13G/A
Feb 09, 2023	vanguard group inc	8.94%	25,421,347	SC 13G/A
Feb 07, 2023	blackrock inc.	8.4%	23,781,609	SC 13G/A
Feb 14, 2022	price t rowe associates inc /md/	7.0%	20,016,331	SC 13G
Feb 09, 2022	vanguard group inc	8.48%	24,176,366	SC 13G/A
Feb 08, 2022	blackrock inc.	7.5%	21,348,508	SC 13G/A

Recent SEC filings of Becton Dickinson and Co

View All Filings

Date Filed	Form Type	Document
May 06, 2024	4	Insider Trading
May 06, 2024	4	Insider Trading
May 02, 2024	10-Q	Quarterly Report
May 02, 2024	8-K	Current Report
May 02, 2024	S-3ASR	S-3ASR
May 01, 2024	4	Insider Trading
Apr 30, 2024	144	Notice of Insider Sale Intent
Apr 05, 2024	4	Insider Trading
Mar 15, 2024	4	Insider Trading
Mar 14, 2024	144	Notice of Insider Sale Intent

Peers (Alternatives to Becton Dickinson and Co)

Name	Mkt Capsorted ascending	Revenue	Price %, 1M	Returns, 1Y	P/E	P/S	Rev 1-Yr	Inc 1-Yr
LARGE-CAP
ABT	184.5B	40.3B	-4.60%	-4.35%	32.81	4.58	-2.84%	-3.08%
BDX	68.5B	19.7B	-3.65%	-5.69%	51.42	3.48	4.82%	-17.56%
ALGN	21.6B	3.9B	-9.77%	-6.38%	46.66	5.51	5.72%	46.72%
BAX	18.4B	14.9B	-15.25%	-20.81%	6.95	1.24	2.98%	207.68%
MID-CAP
ATR	9.9B	3.5B	5.58%	23.16%	31.71	2.8	6.16%	35.06%
HSIC	9.1B	12.5B	-1.81%	-10.76%	23.5	0.73	-0.61%	-18.83%
BIO	8.2B	2.7B	-13.87%	-26.12%	-12.81	3.06	-4.68%	82.43%
XRAY	5.9B	3.9B	-12.53%	-31.61%	-62.76	1.49	0.23%	91.03%
AXNX	3.4B	387.1M	-0.62%	22.51%	-215.76	8.88	30.82%	65.57%
PDCO	2.3B	6.6B	-0.84%	-0.80%	12.05	0.35	2.78%	-0.87%
SMALL-CAP
AHCO	1.3B	3.2B	-6.97%	-19.30%	-1.87	0.4	7.94%	-1661.78%
ANIK	420.5M	166.7M	10.85%	9.31%	-5.09	2.52	6.67%	-456.34%
ANGO	245.9M	324.0M	-12.80%	-31.58%	-1.28	0.76	-3.19%	-337.41%
APYX	48.8M	52.3M	-6.00%	-59.48%	-2.61	0.93	17.61%	19.28%
AEMD	3.4M	3.7M	-25.71%	271.43%	-0.27	0.89	5.77%	8.23%

Becton Dickinson and Co News

Latest updates

Becton Dickinson and Co Earnings Report: Key Takeaways & Analysis

Income Statement (Last 12 Months)

(In Millions)

(*) denotes actual numbers (not divided by Millions)
Income Statement (Quarterly)																					(In Millions)
Description	(%) Q/Q	2024Q1	2023Q4	2023Q3	2023Q2	2023Q1	2022Q4	2022Q3	2022Q2	2022Q1	2021Q4	2021Q3	2021Q2	2021Q1	2020Q4	2020Q3	2020Q2	2020Q1	2019Q4	2019Q3	2019Q2	2019Q1
Revenue	7.2%	5,045	4,706	5,087	4,878	4,821	4,586	4,761	4,641	4,750	4,718	4,576	4,607	4,907	5,315	4,784	3,855	4,253	4,225	4,584	4,350	4,195
Costs and Expenses	1.0%	4,311	4,267	4,738	4,329	4,193	4,001	4,272	4,104	4,185	4,027	4,345	4,114	4,473	4,074	4,057	3,497	3,884	3,724	4,474	3,725	4,059
S&GA Expenses	-1.6%	1,193	1,213	1,138	1,190	1,205	1,187	1,183	1,149	1,192	1,185	1,254	1,200	1,148	1,149	1,059	980	1,025	1,121	1,094	1,076	1,089
R&D Expenses	3.1%	299	290	281	306	337	313	300	315	327	314	355	330	317	291	243	262	264	270	270	282	252
EBITDA Margin	1.6%	0.22*	0.22*	0.23*	0.24*	0.24*	0.23*	0.23*	0.22*	0.22*	0.21*	0.23*	0.21*	0.21*	0.21*	0.18*	0.21*	0.22*	0.21*	0.24*	-	-
Interest Expenses	12.6%	125	111	113	119	118	102	104	99.00	97.00	98.00	112	115	124	118	123	135	134	136	141	156	171
Income Taxes	24.7%	96.00	77.00	28.00	64.00	68.00	-28.00	33.00	31.00	52.00	32.00	-24.00	-28.00	6.00	154	-34.00	-38.00	17.00	117	-164	9.00	-17.00
Earnings Before Taxes	76.3%	633	359	181	471	529	481	320	421	442	600	2.00	378	305	1,157	-428	248	200	394	-1.50	460	3.00
EBT Margin	5.5%	0.08*	0.08*	0.09*	0.09*	0.09*	0.09*	0.09*	0.08*	0.08*	0.07*	0.09*	0.07*	0.07*	0.06*	0.02*	0.05*	0.06*	0.05*	0.07*	-	-
Net Income	91.1%	537	281	108	407	460	509	288	360	454	677	265	525	299	1,003	128	286	183	278	163	451	20.00
Net Income Margin	4.9%	0.07*	0.06*	0.08*	0.09*	0.09*	0.09*	0.09*	0.09*	0.10*	0.09*	0.11*	0.10*	0.09*	0.09*	0.05*	0.05*	0.06*	0.05*	0.07*	-	-
Free Cashflow	-48.6%	380	739	1,031	890	4.00	191	658	425	68.00	347	389	321	935	1,287	707	660	261	540	1,013	-	-

Balance Sheet

(In Millions)

(*) denotes actual numbers (not divided by Millions)
Balance Sheet																					(In Millions)
Description	(%) Q/Q	2024Q1	2023Q4	2023Q3	2023Q2	2023Q1	2022Q4	2022Q3	2022Q2	2022Q1	2021Q4	2021Q3	2021Q2	2021Q1	2020Q4	2020Q3	2020Q2	2020Q1	2019Q4	2019Q3	2019Q2	2019Q1
Assets	3.6%	54,157	52,274	52,780	53,017	54,394	53,129	52,934	53,199	54,786	53,363	53,866	54,333	54,921	54,748	54,012	53,959	53,516	51,952	51,765	52,233	52,598
Current Assets	26.8%	10,340	8,156	8,676	8,588	9,587	8,175	8,141	9,547	10,152	8,307	8,838	9,538	10,000	9,537	8,969	8,827	8,555	6,438	6,664	6,781	6,844
Cash Equivalents	102.9%	2,394	1,180	1,416	923	1,981	744	1,159	2,759	3,320	2,047	2,392	3,282	3,898	3,447	2,917	2,964	2,439	609	590	594	767
Inventory	-2.3%	3,229	3,304	3,273	3,588	3,656	3,604	3,224	3,163	3,258	3,035	2,743	2,947	2,895	2,814	2,743	2,945	2,793	2,760	2,579	2,629	2,627
Net PPE	-0.8%	6,591	6,647	6,557	6,474	6,356	6,247	6,012	6,005	6,406	6,384	6,003	6,164	6,142	6,096	5,923	5,841	5,664	5,782	5,659	5,550	5,473
Goodwill	-0.1%	24,566	24,597	24,522	24,584	24,780	24,763	24,621	23,968	24,096	24,116	23,886	23,814	23,772	23,758	23,604	23,549	23,415	23,435	23,376	23,498	23,513
Current Liabilities	-2.8%	7,327	7,540	6,641	6,878	7,304	7,625	7,811	7,080	6,657	6,735	6,626	7,749	5,376	7,021	5,836	6,067	8,755	6,726	5,655	6,237	7,108
Long Term Debt	13.5%	15,995	14,094	14,738	14,926	16,010	14,268	13,886	14,683	199	16,360	17,110	15,700	1,005	265	17,224	500	16,809	16,949	18,081	18,016	249
LT Debt, Non Current	-100.0%	-	14,094	14,738	14,926	16,010	14,268	13,886	14,683	199	16,360	17,110	15,700	1,005	265	17,224	500	16,809	16,949	18,081	18,016	249
Shareholder's Equity	1.2%	25,647	25,332	25,796	25,937	15,563	19,590	365	24.00	19,495	24.00	23.00	24,135	23.00	365	365	19,228	23.00	12,938	23.00	23.00	347
Retained Earnings	1.7%	15,802	15,540	15,535	15,691	15,563	15,384	15,157	15,088	14,416	14,233	13,826	13,821	13,557	13,522	12,791	12,916	12,868	12,938	12,913	12,997	12,792
Additional Paid-In Capital	0.3%	19,795	19,741	19,720	19,681	19,639	19,590	19,553	19,511	19,495	19,435	19,272	19,282	19,341	19,301	19,270	19,228	16,288	16,320	16,270	16,227	16,177
Accumulated Depreciation	1.1%	7,334	7,253	7,021	7,002	6,848	6,679	6,402	6,399	6,788	6,648	6,090	6,487	6,277	6,177	5,996	5,819	5,598	5,643	5,469	5,491	5,402
Shares Outstanding	0.0%	289	289	-	290	284	284	-	285	285	292	-	294	298	298	-	297	279	278	-	277	276
Float	-	-	-	-	-	70,253	-	-	-	74,866	-	-	-	70,616	-	-	-	62,360	-	-	-	67,279

Cashflow (Last 12 Months)

(In Millions)

(*) denotes actual numbers (not divided by Millions)
Cashflow (Quarterly)																					(In Millions)
Description	(%) Q/Q	2024Q1	2023Q4	2023Q3	2023Q2	2023Q1	2022Q4	2022Q3	2022Q2	2022Q1	2021Q4	2021Q3	2021Q2	2021Q1	2020Q4	2020Q3	2020Q2	2020Q1	2019Q4	2019Q3	2019Q2	2019Q1
Cashflow From Operations	-39.9%	514	855	1,325	1,081	185	399	973	678	290	530	841	564	1,188	1,533	879	862	483	713	1,371	932	782
Share Based Compensation	-27.7%	60.00	83.00	58.00	56.00	56.00	89.00	49.00	50.00	53.00	81.00	47.00	44.00	55.00	83.00	43.00	52.00	59.00	82.00	53.00	56.00	59.00
Cashflow From Investing	-353.2%	-1,056	-233	137	-329	-233	-291	-2,005	-236	-297	-682	-681	-299	-433	-430	-285	-363	-255	-287	-441	-330	-269
Cashflow From Financing	297.8%	1,705	-862	-997	-1,794	1,369	-534	-549	-846	986	-327	-1,142	-1,271	-301	-592	-1,208	20.00	1,623	-413	-923	-768	-798
Dividend Payments	-100.0%	-	275	265	286	282	281	270	271	270	271	259	261	264	264	253	268	253	252	247	246	246
Buy Backs	-100.0%	-	500	-	-	-	-	500	-	-	-	750	-	-	-	-	-	-	-	-	-	-

Get Full Access to Grufity – and Unlimited Downloads

Gain full access to fair value, watchlists, stock screener, unlimited page visits, and additional features by joining as a member today for just $1.99.

Try For Just $1.99

BDX Income Statement

2024-03-31

Condensed Consolidated Statements of Income - USD ($) $ in Millions	3 Months Ended		6 Months Ended
	Mar. 31, 2024	Mar. 31, 2023	Mar. 31, 2024	Mar. 31, 2023
Income Statement [Abstract]
Revenues	$ 5,045	$ 4,821	$ 9,751	$ 9,407
Cost of products sold	2,741	2,586	5,420	5,038
Selling and administrative expense	1,193	1,205	2,406	2,392
Research and development expense	299	337	589	651
Integration and restructuring expense	101	62	176	106
Other operating (income) expense, net	(23)	4	(12)	7
Total Operating Costs and Expenses	4,311	4,193	8,578	8,193
Operating Income	734	628	1,173	1,213
Interest expense	(125)	(118)	(236)	(220)
Interest income	26	10	60	16
Other (expense) income, net	(2)	8	(6)	1
Income Before Income Taxes	633	529	991	1,009
Income tax provision	96	68	173	40
Net Income	537	460	818	969
Preferred stock dividends	0	(23)	0	(45)
Net income applicable to common shareholders	$ 537	$ 438	$ 818	$ 924
Basic Earnings per Share (USD per share)	$ 1.85	$ 1.54	$ 2.82	$ 3.25
Diluted Earnings per Share (USD per share)	1.85	1.53	2.81	3.24
Dividends per Common Share (USD per share)	$ 0.95	$ 0.91	$ 1.90	$ 1.82

BDX Balance Sheet

2024-03-31

Condensed Consolidated Balance Sheets - USD ($) $ in Millions	Mar. 31, 2024	Sep. 30, 2023
Current Assets:
Cash and equivalents	$ 2,348	$ 1,416
Restricted cash	46	65
Short-term investments	827	8
Trade receivables, net	2,559	2,534
Inventories:
Materials	777	714
Work in process	376	381
Finished products	2,076	2,178
Inventories	3,229	3,273
Prepaid expenses and other	1,330	1,380
Total Current Assets	10,340	8,676
Property, Plant and Equipment	13,925	13,578
Less allowances for depreciation and amortization	7,334	7,021
Property, Plant and Equipment, Net	6,591	6,557
Goodwill	24,566	24,522
Developed Technology, Net	7,538	8,058
Customer Relationships, Net	2,164	2,338
Other Intangibles, Net	558	552
Other Assets	2,399	2,078
Total Assets	54,157	52,780
Current Liabilities:
Current debt obligations	2,016	1,141
Payables, accrued expenses and other current liabilities	5,311	5,500
Total Current Liabilities	7,327	6,641
Long-Term Debt	15,995	14,738
Long-Term Employee Benefit Obligations	890	1,023
Deferred Income Taxes and Other Liabilities	4,297	4,582
Commitments and Contingencies (See Note 5)
Shareholders’ Equity
Common stock — $1 par value; authorized — 640,000,000 shares; issued — 370,594,401 shares in March 31, 2024 and September 30, 2023	371	371
Capital in excess of par value	19,795	19,720
Retained earnings	15,802	15,535
Deferred compensation	26	24
Treasury stock	(8,811)	(8,305)
Accumulated other comprehensive loss	(1,535)	(1,548)
Total Shareholders’ Equity	25,647	25,796
Total Liabilities and Shareholders’ Equity	$ 54,157	$ 52,780

About Becton Dickinson and Co

Becton, Dickinson and Company develops, manufactures, and sells medical supplies, devices, laboratory equipment, and diagnostic products for healthcare institutions, physicians, life science researchers, clinical laboratories, pharmaceutical industry, and the general public worldwide. The company's BD Medical segment provides peripheral intravenous (IV) and advanced peripheral catheters, central lines, acute dialysis catheters, vascular care and preparation products, needle-free IV connectors and extensions sets, closed-system drug transfer devices, hazardous drug detections, hypodermic syringes and needles, anesthesia needles and trays, enteral syringes, and sharps disposal systems; IV medication and infusion therapy delivery systems, medication compounding workflow systems, automated medication dispensing and supply management systems, and medication inventory optimization and tracking systems; syringes, pen needles, and other products for diabetes; and prefillable drug delivery systems. Its BD Life Sciences segment offers specimen and blood collection products; automated blood and tuberculosis culturing, molecular testing, microorganism identification and drug susceptibility, and liquid-based cytology systems, as well as rapid diagnostic assays, microbiology laboratory automation products, and plated media products; and fluorescence-activated cell sorters and analyzers, antibodies and kits, reagent systems, and solutions for single-cell gene expression analysis, as well as clinical oncology, immunological, and transplantation diagnostic/monitoring reagents and analyzers. The company's BD Interventional segment provides hernia and soft tissue repair, biological and bioresorbable grafts, biosurgery, and other surgical products; surgical infection prevention, surgical and laparoscopic instrumentation products; peripheral intervention products; and urology and critical care products. The company was founded in 1897 and is based in Franklin Lakes, New Jersey.

CEO	Mr. Thomas E. Polen Jr.
WEBSITE	bd.com
INDUSTRY	Medical Instruments & Supplies
EMPLOYEES	65535

Becton Dickinson and Co Frequently Asked Questions

What is the ticker symbol for Becton Dickinson and Co? What does BDX stand for in stocks?

BDX is the stock ticker symbol of Becton Dickinson and Co. Every public company that trades on a stock exchange gets a ticker symbol.

What is the market capital of Becton Dickinson and Co (BDX)?

As of Tue May 07 2024, market cap of Becton Dickinson and Co is 68.55 Billion. The market capitalization is calculated by multiplying the stock price with the number of shares outstanding.

What is the fair value of BDX stock?

You can check BDX's fair value in chart for subscribers.

What is the fair value of BDX stock?

You can check BDX's fair value in chart for subscribers. The fair value of Becton Dickinson and Co is provided for various growth and macro-economic scenarios from very pessimiatic to very optimistic assumptions. These fair values are estimates from Grufity's Fair Value model based on company's past performance. However, past performance of Becton Dickinson and Co is no guarantee of future performance. These fairvalue estimates should only be used as one of the inputs in your stock analysis. We provide model's historical fair value estimates for BDX so that you know how good or bad the model has been in the past so you can discard it if needed. There are others that provide fair values of stocks such as wallmine, finbox, gurufocus and finviz. Most provide point in time estimates. We provide a history of our models fair value estimates so that you can get a sense of it's usefulness. Otherwise this data point is of little use.

Is Becton Dickinson and Co a good stock to buy?

The fair value guage provides a quick view whether BDX is over valued or under valued. Whether Becton Dickinson and Co is cheap or expensive depends on the assumptions which impact Becton Dickinson and Co's fair value. We provide several scenarios of inflation and growth to encompass these range of assumptions for BDX.

What is Becton Dickinson and Co's Price to Earnings (PE) and Price to sales (PS) ratio?

As of Tue May 07 2024, BDX's PE ratio (Price to Earnings) is 51.42 and Price to Sales (PS) ratio is 3.48. The price to earnings and price to sales ratio are two most important valuation metrics for any company. PE ratio tell us the number of years of earnings investors are ready to pay for owning the company. Historically, S&P500 price to earnings ratio has fallen below 12 during periods of gloom and gone past 30 during periods of euphoria. BDX PE ratio will change depending on the future growth rate expectations of investors.

What is 5 year return on Becton Dickinson and Co's stock?

In the past 10 years, Becton Dickinson and Co has provided 0.09 (multiply by 100 for percentage) rate of return.